Fertility and sterility最新文献

{"title":"(Not) My body, my choice?","authors":"Eve C. Feinberg M.D.","doi":"10.1016/j.fertnstert.2024.11.012","DOIUrl":"10.1016/j.fertnstert.2024.11.012","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 199-200"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-based guideline: Premature Ovarian Insufficiency† ‡","authors":"Nick Panay , Richard A. Anderson , Amy Bennie , Marcelle Cedars , Melanie Davies , Carolyn Ee , Claus H. Gravholt , Sophia Kalantaridou , Amanda Kallen , Kimberly Q. Kim , Micheline Misrahi , Aya Mousa , Rossella E. Nappi , Walter A. Rocca , Xiangyan Ruan , Helena Teede , Nathalie Vermeulen","doi":"10.1016/j.fertnstert.2024.11.007","DOIUrl":"10.1016/j.fertnstert.2024.11.007","url":null,"abstract":"<div><h3>Study Question</h3><div>How should premature/primary ovarian insufficiency (POI) be diagnosed and managed, based on the best available evidence from published literature?</div></div><div><h3>Summary Answer</h3><div>The current guideline provides 145 recommendations on symptoms, diagnosis, causation, sequelae and treatment of POI.</div></div><div><h3>What is Known Already</h3><div>Premature ovarian insufficiency (POI) presents a significant challenge to women's health, with far-reaching implications, both physically and emotionally. The potential implications include adverse effects on quality of life; fertility; and bone, cardiovascular and cognitive health. Although hormone therapy (HT) can mitigate some of these effects, many questions still remain regarding the optimal management of POI.</div></div><div><h3>Study Design, Size, Duration</h3><div>The guideline was developed according to the structured methodology for development of ESHRE guidelines. Key questions were determined by a group of experts and informed by a scoping survey of women and health care professionals. Literature searches and assessment were then performed. Papers published up to January 30<sup>th</sup>, 2024, and written in English were included in the guideline. An integrity review was conducted for the randomised controlled trials (RCTs) on POI included in the guideline.</div></div><div><h3>Participants/Materials, Setting, Methods</h3><div>Based on the collected evidence, recommendations were formulated and discussed within the guideline development group until consensus was reached. Women with lived experience of POI informed the recommendations in general, and particularly on those on provision of care. A stakeholder review was organised after finalisation of the draft. The final version was approved by the guideline development group and the ESHRE Executive Committee.</div></div><div><h3>Main Results and The Role of Chance</h3><div>New data indicate a higher prevalence of POI, 3.5%, than was previously thought. This guideline aims to help health care professionals to apply best practice care for women with POI. The recent update of the POI guideline covers 40 clinical questions on diagnosis of the condition, the different sequelae, including bone, cardiovascular, neurological and sexual function, fertility and general well-being, and treatment options, including hormone therapy. The list of clinical questions was expanded from the previous iteration of the guideline (2015) based on the scoping survey and appreciation of emerging knowledge of POI.</div><div>Questions were added on the role of anti-Müllerian hormone (AMH) in the diagnosis of POI, fertility preservation, muscle health, and specific considerations for HT in iatrogenic POI. Additionally, the topic on complementary treatments was extended with specific focus on non-hormonal treatments and lifestyle management options.</div><div>Significant changes from the previous 2015 guideline include the recommen","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 221-236"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting a successful match among applicants to reproductive endocrinology and infertility fellowship","authors":"Leigh A. Humphries M.D., M.S.C.E. , Jeremy Applebaum M.D. , Monica A. Mainigi M.D. , Caitlin E. Martin M.D., M.S. , Divya K. Shah M.D., M.M.E.","doi":"10.1016/j.fertnstert.2024.08.337","DOIUrl":"10.1016/j.fertnstert.2024.08.337","url":null,"abstract":"<div><h3>Objective</h3><div>To identify independent predictors of a successful match to reproductive endocrinology and infertility (REI) fellowships, and to develop and internally validate a prediction model for REI match results.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Subjects</h3><div>Reproductive endocrinology and infertility fellowship applications sent to the University of Pennsylvania from 2019 to 2023 (excluding 2020), which represented nearly all REI applicants nationally according to National Resident Matching Program data.</div></div><div><h3>Exposure</h3><div>Demographics, education, training, and academic achievements.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Match result, confirmed through online search and communication with program administrators. Univariate analyses identified variables associated with match, which were then included in multivariable models to identify independent predictors. Bootstrapping was used to assess model discrimination and calibration. The final model was integrated into a web-based tool.</div></div><div><h3>Result(s)</h3><div>Of 286 applications (99.0% of REI applications to the National Resident Matching Program), 199 (69.6%) resulted in a successful match. In univariate analyses, variables associated with match were younger age, attendance at an allopathic US medical school, United States Medical Licensing Examination (USMLE) and Council on Resident Education in Obstetrics and Gynecology scores, residency rank, residency affiliation with a fellowship, research experiences, first-author publications, abstracts/articles in progress, and poster presentations. In the adjusted model, independent predictors of match included residency affiliation with an REI fellowship (adjusted odds ratio [aOR], 5.43; 2.02–14.64), residency rank (aOR, 1.77; 1.25–2.50), USMLE score (aOR, 1.05; 1.02–1.08), at least one first-author publication (aOR, 2.32; 1.08–4.96), projects in progress (aOR, 1.26; 1.02–1.55), and poster presentations (aOR, 1.07; 1.00–1.15). Attendance at an international medical school was a negative predictor (aOR, 0.32; 0.11–0.88). The model achieved an area under the curve of 0.883, with 88.5% sensitivity and 65.8% specificity. A refined model without USMLE scores maintained strong performance (C-statistic, 0.85; 0.81–0.91; calibration slope, 0.91; 0.72–1.24).</div></div><div><h3>Conclusion(s)</h3><div>Affiliation with an REI fellowship, residency reputation, and research output strongly predicted match success. Gender, race, and ethnicity were not major predictors, yet underrepresentation of certain racial and ethnic groups limited the power to detect potential differences. Our prediction model correctly classified >75% of candidates’ match results. These findings may help candidates optimize applications and estimate chances of a successful match into REI fellowship, as well as assist programs in critically reviewing their selection criteria ","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 333-341"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Embryoscopy with hysteroscopy for a more full-scope assessment and management of early miscarriage","authors":"Salomeh Salari M.D., M.S. , Steven R. Lindheim M.D., M.M.M.","doi":"10.1016/j.fertnstert.2024.11.022","DOIUrl":"10.1016/j.fertnstert.2024.11.022","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 239-240"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between primary ovarian insufficiency and increased multimorbidity in a large prospective cohort (Canadian Longitudinal Study on Aging)","authors":"Abirami Kirubarajan M.D., M.Sc. , Nazmul Sohel Ph.D. , Alexandra Mayhew Ph.D. , Lauren E. Griffith Ph.D. , Parminder Raina Ph.D. , Alison K. Shea M.D., Ph.D.","doi":"10.1016/j.fertnstert.2024.08.345","DOIUrl":"10.1016/j.fertnstert.2024.08.345","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the prevalence of multimorbidity among individuals with primary ovarian insufficiency (POI) and early menopause compared with those with the average age of menopause.</div></div><div><h3>Design</h3><div>Prospective cohort.</div></div><div><h3>Subjects</h3><div>This prospective cohort encompassed female postmenopausal individuals from the Canadian Longitudinal Study on Aging. The Canadian Longitudinal Study on Aging collected cross-sectional data from 50,000 community-dwelling Canadians aged 45–85 years between 2010 and 2015.</div></div><div><h3>Exposure</h3><div>The primary exposure was POI (defined by onset of menopause at the age of <40 years). Comparators included average age of menopause (age, 46–55 years), early menopause (40–45 years), and late-onset menopause (56–65 years) and those who underwent hysterectomy.</div></div><div><h3>Main Outcome Measure(s)</h3><div>The primary outcome was multimorbidity, which was defined as two or more chronic conditions. The secondary outcomes were severe multimorbidity (defined as 3 or more chronic conditions) and frequencies of specific chronic conditions among a comprehensive list of 15 individual conditions. We assessed the association between multimorbidity and age at menopause using logistic regression and odds ratios (ORs), with confidence intervals (CIs) set at 95%. The ORs were adjusted for known predictors of multimorbidity, including age, menopausal hormone therapy, education, ethnicity, self-reported loneliness, living alone, body mass index, smoking habits, nutritional risk, social participation, and physical activity.</div></div><div><h3>Result(s)</h3><div>A total of 12,339 postmenopausal participants were included, of whom 374 (3.0%) experienced POI and 1,396 (11.3%) experienced early menopause. The prevalence rates of multimorbidity were 64.8% and 51.1% among those with POI and early menopause, respectively. In contrast, only 43.9% of individuals with average age of menopause (age, 46–55 years) had multimorbidity. The OR for multimorbidity in the POI population was 2.5 (95% CI, 2.0–3.1) compared with that in individuals who had the average age of menopause. This relationship was maintained after adjustment for confounders (adjusted OR [aOR], 2.0; 95% CI, 1.5–2.5). The prevalence of severe multimorbidity was also double in the POI group compared with that in the average age group (39.2% vs. 21.1%). There were significantly increased risks of ischemic heart disease (aOR, 2.8; 95% CI, 1.7–4.7), gastric ulcers (aOR, 1.6; 95% CI, 1.1–2.3), and osteoporosis (aOR, 1.6; 95% CI, 1.2–2.1) in the POI group.</div></div><div><h3>Conclusion(s)</h3><div>Individuals with POI and early menopause experience increased multimorbidity compared with those undergoing menopause at an average age. This trend persists even after adjusting for significant multimorbidity risk factors.</div></div><div><div>Asociación entre insuficiencia ovárica primaria y incremento en la multi","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 289-299"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"United Kingdom data collection of semen quality in transgender adolescent females seeking fertility preservation","authors":"Philippa Ralph M.B.B.S. , Mohammed Mahoud M.B.B.S. , Daniel Schlager M.B.B.S. , Wai Gin Lee M.B.B.S. , Raheala Wafa M.Sc. , Elizabeth Williamson M.Sc. , Gary Butler M.D. , David Ralph M.B.B.S. , Philippa Sangster M.B.B.S.","doi":"10.1016/j.fertnstert.2024.09.006","DOIUrl":"10.1016/j.fertnstert.2024.09.006","url":null,"abstract":"<div><h3>Objective</h3><div>Increasing numbers of adolescents with gender dysphoria start gonadotropin-releasing hormone agonists to halt puberty, minimizing psychological distress. The uncertainty of long-term effects of this medication, and the subsequent likelihood of accessing gender-affirming hormone treatment, highlights the importance of fertility preservation before starting hormone treatment. We investigated the take-up, hormonal profile, and sperm quality in adolescents undergoing fertility preservation via cryopreservation by masturbation or surgical sperm retrieval, before starting hormonal therapy.</div></div><div><h3>Design</h3><div>Data were prospectively maintained from a tertiary UK-based hospital. A total of 122 people <19 years, mean age 15.2 ± 1.7 years, referred by gender clinics and general practitioners, were included in this cohort study.</div></div><div><h3>Subjects</h3><div>Participants were counseled for fertility preservation, and serum testosterone, follicle-stimulating hormone, and luteinizing hormone levels were recorded before providing semen samples.</div></div><div><h3>Exposure</h3><div>Masturbation semen samples were classified as normal (>15 mil/mL), oligozoospermia (1–15 mil/mL), cryptozoospermia (<1 mil/mL), or azoospermia. If the sample was insufficient or the person was unwilling to masturbate, surgical sperm retrieval was offered in a stepwise manner using electroejaculation, testicular sperm extraction (TESE) ± microdissection testicular sperm extraction (mTESE).</div></div><div><h3>Main Outcome Measures</h3><div>Quality of semen produced by participants, via masturbation or surgical sperm retrieval, was analyzed to determine if it was good enough to cryopreserve for future fertility use.</div></div><div><h3>Results</h3><div>Of 122 participants, 23 (19%) declined sample storage. In the masturbation group (average age, 16.3 years), 78 people produced 106 samples. Of 106 samples, 86 were stored—43.7% were normospermic, 35.9% oligozoospermic, 8.7% cryptozoospermic, and 11.7% azoospermic. Overall, semen parameters varied but were generally abnormal, illustrated by only 43.7% of the masturbation samples produced being normospermic. For surgical sperm retrieval subjects (average age, 15.2 years), electroejaculation was successful in 4 of 21 people, whereas the rest proceeded with TESE/mTESE. Encouragingly, 16 of 21 subjects had an average of 5 vials stored, and all participants had a testosterone level >8 nmol/L. Semen parameters in this subcohort were poor but possibly adequate for intracytoplasmic sperm injection.</div></div><div><h3>Conclusions</h3><div>In this large database of transgender girls referred for fertility preservation in the United Kingdom, fertility preservation is possible, even with those unwilling to masturbate. Long-term data are required to check the health of these gametes, observing live birth rates using these preserved gametes.</div></div><div><div>Recolección de datos sob","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 313-321"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of in vitro fertilization with severe maternal morbidity in low-risk patients without comorbidities","authors":"Rachel Solmonovich M.D. , Insaf Kouba M.D. , Frank I. Jackson D.O. , Alejandro Alvarez M.P.H. , Randi H. Goldman M.D. , Gabriel San Roman M.D. , Matthew J. Blitz M.D., M.B.A.","doi":"10.1016/j.fertnstert.2024.09.015","DOIUrl":"10.1016/j.fertnstert.2024.09.015","url":null,"abstract":"<div><h3>Objective</h3><div>To determine whether an association exists between in vitro fertilization (IVF) and severe maternal morbidity among low-risk pregnant patients.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Subjects</h3><div>Low-risk pregnant patients who delivered between January 2019 and December 2022. Low-risk was defined as having an obstetric comorbidity index score of 0.</div></div><div><h3>Exposure</h3><div>In vitro fertilization.</div></div><div><h3>Main Outcome Measure(s)</h3><div>The primary outcome (dependent variable) was any severe maternal morbidity. The secondary outcome was the need for a cesarean delivery. A modified Poisson regression with robust error variance was used to model the probability of severe maternal morbidity as a function of IVF. Risk ratios and their associated 95% confidence intervals (CIs) were computed. An α value of 0.05 was considered statistically significant.</div></div><div><h3>Result(s)</h3><div>A total of 39,668 pregnancies were included for analysis, and 454 (1.1%) were conceived by IVF. The overall severe maternal morbidity rate was 2.4% (n = 949), with the most common indicator being blood transfusion. The overall cesarean delivery rate was 18.8% (n = 7,459). On modified Poisson regression, IVF-conceived pregnancies were associated with 2.56 times the risk of severe maternal morbidity (95% CI, 1.73–3.79) and 1.54 times the risk of having a cesarean delivery (95% CI, 1.37–1.74) compared with non-IVF pregnancies.</div></div><div><h3>Conclusion(s)</h3><div>In vitro fertilization is associated with higher rates of severe maternal morbidity, primarily the need for a blood transfusion, and cesarean delivery in low-risk pregnancies without major comorbidities. Recognizing this association allows healthcare providers to implement proactive measures for better monitoring and tailored postpartum care.</div></div><div><div>Asociación Entre La Fecundación in Vitro Y Morbilidad Materna Severa en Pacientes de Bajo Riesgo Sin Comorbilidades</div></div><div><h3>Objetivo</h3><div>Determinar si existe asociación entre la fecundación in vitro (FIV) y la morbilidad materna severa en pacientes gestantes de bajo riesgo.</div></div><div><h3>Diseño</h3><div>Estudio retrospectivo de cohortes.</div></div><div><h3>Entorno</h3><div>Sistema sanitario universitario.</div></div><div><h3>Paciente(s)</h3><div>Pacientes gestantes de bajo riesgo que dieron a luz entre junio de 2019 y diciembre de 2022. Se definió bajo riesgo cuando la puntuación del índice de comorbilidad obstétrico era de 0.</div></div><div><h3>Intervención(es)</h3><div>Fecundación in vitro.</div></div><div><h3>Medida principal de resultado</h3><div>El resultado principal (variable dependiente) fue cualquier morbilidad materna severa. El objetivo secundario fue la necesidad de nacimiento por cesárea. El modelo utilizado para calcular la probabilidad de morbilidad materna grave en función de la FIV fue una regresión de ","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 262-269"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stepwise approach of hysteroscopic cytoreductive surgery for adenomyosis in patients with recurrent implantation failure","authors":"Rudi Campo M.D. , Evy Gillet M.D. , Stephan Gordts M.D. , Marion Valkenburg M.D. , Helena Van Kerrebroeck M.D. , Alessa Sugihara M.D. , Istvan Argay M.D. , Panayiotis Tanos M.D.","doi":"10.1016/j.fertnstert.2024.10.051","DOIUrl":"10.1016/j.fertnstert.2024.10.051","url":null,"abstract":"<div><h3>Objective</h3><div>To study the value of hysteroscopic cytoreductive surgery for adenomyotic lesions to improve reproductive outcomes. We describe a feasible and novel minimal invasive stepwise approach, which did not result in postoperative adhesion formation and restored favorable reproductive outcomes.</div></div><div><h3>Design</h3><div>Video article.</div></div><div><h3>Subjects</h3><div>Patients aged <37 years, diagnosed with adenomyotic lesions by ultrasound and/or magnetic resonance imaging, who after a minimum of 6 months of medical treatment (gonadotrophin releasing hormone agonist or dienogest) failed to conceive with a minimum of two embryo transfer cycles of high-quality blastocysts were included.</div></div><div><h3>Exposure</h3><div>The procedure was performed under conscious sedation, level 3b in an ambulatory surgical center. All patients received hormonal suppressive treatment (Dienogest 2 mgr per day or Triptoreline 3.75 mgr. IM once a month). Institutional Review Board approval and patient consent had been received for the study. The surgical steps included the following:<ul><li><span>•</span><span><div>Identification of the inner myometrial lesion by combined ultrasonographic-hysteroscopic examination.</div></span></li><li><span>•</span><span><div>Incision of the lesion at the midline with a 15-Fr bipolar mini-resectoscope until the pathological adenomyotic tissue was totally removed. In contrast to ultrasound and magnetic resonance imaging, hysteroscopy can visualize a clear tissue structure difference between the adenomyotic fibrotic lesion and the surrounding healthy myometrium. Intermittent transvaginal ultrasound is mandatory to control the myometrial security zone, which should not be <1 cm.</div></span></li><li><span>•</span><span><div>Removal of the side wall pathological tissue, using the same hysteroscopic visual references, aiming to avoid thermal injury to the surrounding healthy myometrial layer.</div></span></li><li><span>•</span><span><div>Application of hyaluronic acid antiadhesive barrier gel under hysteroscopic vision.</div></span></li><li><span>•</span><span><div>Second-look hysteroscopy was scheduled after 8 weeks.</div></span></li></ul></div></div><div><h3>Main Outcome Measure(s)</h3><div>Feasibility, reproductive outcomes, and complications (adhesions and placental disorders).</div></div><div><h3>Result(s)</h3><div>Fifteen patients underwent surgery and had histological confirmation of adenomyosis. Second-look hysteroscopy was possible in 13 of 15 women (2 spontaneous pregnancies) with reassuring postoperative results, showing only mild lateral wall adhesions in three cases. Pregnancy was registered in 12 women: one early miscarriage; seven ongoing pregnancies; and four deliveries of healthy infants with normal birth weight and no placenta-related complications.</div></div><div><h3>Conclusion</h3><div>(s): In contrast to the current beliefs, mini hysteroscopy can identify and selectively r","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 370-372"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To be frank: is it time to say goodbye to Abbe-McIndoe and Vecchietti?","authors":"Marisa Imbroane B.S. , Allison Bosch M.D. , Elliott G. Richards M.D., Ph.D.","doi":"10.1016/j.fertnstert.2024.12.004","DOIUrl":"10.1016/j.fertnstert.2024.12.004","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 251-252"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulsatile gonadotropin-releasing hormone therapy: comparison of efficacy between functional hypothalamic amenorrhea and congenital hypogonadotropic hypogonadism","authors":"Hortense Everaere M.D. , Virginie Simon M.D. , Anne Bachelot M.D., Ph.D. , Maxime Leroy B.S. , Christine Decanter M.D. , Didier Dewailly M.D. , Sophie Catteau-Jonard M.D., Ph.D. , Geoffroy Robin M.D.","doi":"10.1016/j.fertnstert.2024.08.354","DOIUrl":"10.1016/j.fertnstert.2024.08.354","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the ongoing pregnancy rate per initiated cycle between patients with functional hypothalamic amenorrhea (FHA) and patients with congenital hypogonadotropic hypogonadism (CHH) treated with pulsatile gonadotropin-releasing hormone (GnRH) administration.</div></div><div><h3>Design</h3><div>Retrospective monocentric cohort study conducted at the University Hospital of Lille from 2004 to 2022.</div></div><div><h3>Subjects</h3><div>A total of 141 patients diagnosed with central suprapituitary amenorrhea during infertility evaluation and subsequently treated with pulsatile GnRH therapy. 111 and 30 patients were diagnosed with FHA or CHH, respectively.</div></div><div><h3>Exposure</h3><div>Pulsatile GnRH administration.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Ongoing pregnancy rate per initiated cycle.</div></div><div><h3>Result(s)</h3><div>Ongoing pregnancy rates per initiated cycle were comparable between groups: 21.5% in the FHA group vs. 22% in the CHH group. Comparison of baseline characteristics showed a more pronounced follicle-stimulating hormone (FSH) deficiency in patients with CHH than in those with FHA: 2.55 (0.6–4.92) vs. 4.80 (3.90–5.70) UI/L. Within the CHH group, basal FSH level was positively associated with the occurrence of ongoing pregnancies (odds ratio, 1.57; 95% confidence interval, 1.11–2.22). In the CHH group, the duration of treatment was higher than in the FHA group: 23.59 (± 8.02) vs. 18.16 (± 7.66) days.</div></div><div><h3>Conclusion(s)</h3><div>The baseline FSH level is lower in patients with CHH than in patients with FHA. The lower the FSH, the lower the chance of pregnancy in patients with CHH. These patients also require more days of GnRH administration. However, the rate of ongoing pregnancies is comparable between the two groups.</div></div><div><div>Terapia hormonal pulsátil liberadora de gonadotropina: Comparación de la eficacia entre la amenorrea hipotalámica funcional y el hipogonadismo hipogonadotrópico congénito</div></div><div><h3>Objetivo</h3><div>Comparar la tasa de embarazo en curso por ciclo iniciado entre pacientes con amenorrea hipotalámica funcional (AHF) y pacientes con hipogonadismo hipogonadotrópico congénito (HHC) tratadas con administración pulsátil de hormona liberadora de gonadotropina (GnRH).</div></div><div><h3>Diseño</h3><div>Estudio de cohorte retrospectivo monocéntrico llevado a cabo en la Universidad Hospital de Lille desde el 2004 al 2022.</div></div><div><h3>Escenario</h3><div>Universidad Hospital de Lille, Departamento de Ginecología Endocrina.</div></div><div><h3>Paciente(s)</h3><div>Un total de 141 pacientes diagnosticas con amenorrea suprapituitaria central durante la evaluación por infertilidad y subsecuentemente tratadas con terapía pulsátil de GnRH. 111 y 30 pacientes fueron diagnosticas con AHF y HHC, respectivamente.</div></div><div><h3>Intervención(es)</h3><div>Administración pulsátil de GnRH.</div></div><div><h3>Medida de result","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 2","pages":"Pages 270-279"},"PeriodicalIF":6.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}